U

Our purpose

To improve life during and beyond sedation

Sedana Medical is a pioneer medtech and pharmaceutical company dedicated to making inhaled sedation a standard therapy in intensive care.

Bringing inhaled sedation to intensive care

We are proud to introduce inhaled sedation to intensive care, a paradigm shift in the care of critically ill patients.

Through the results obtained in the pivotal study with Sedaconda (isoflurane) and Sedaconda ACD*, we have laid the foundation for inhaled sedation in intensive care.

By this, we have also taken a major step closer to our vision – to make inhaled sedation a standard therapy in intensive care.

*formerly known as AnaConDa

Learn more

Sedana Medical Clinical Development Program

We are proud to introduce inhaled sedation to intensive care, a paradigm shift in the care of critically ill patients.

Through the results obtained in the pivotal study with Sedaconda (isoflurane) and Sedaconda ACD*, we have laid the foundation for inhaled sedation in intensive care.

By this, we have also taken a major step closer to our vision – to make inhaled sedation a standard therapy in intensive care.

*formerly known as AnaConDa

Learn more

Sedaconda ACD

Sedaconda ACD (Anaesthetic Conserving Device) is a medical device enabling delivery of inhaled sedation to invasively ventilated patients.

Learn more

Using Sedaconda ACD

Improve your knowledge about our products with our Training Material and Frequently Asked Questions.

Learn more

Our Products

Explore our broad portfolio of products for the administration of inhaled sedation.

Learn more
acd

Sedaconda ACD-S

acd

Sedaconda ACD Starter Kit

Adapter

Adapters

Scavenging-Flurabsorb

Scavenging / Flurabsorb

Bistos-Gas-montior

AMG-06 Gas Monitor

Press Releases

2026

Notice of Annual General Meeting in Sedana Medical
2026-04-24 14:00
Regulatory
The board of directors of Sedana Medical AB (publ) has resolved to convene an annual general meeting of shareholders to be held Wednesday, 27 May 2026...
Sedana Medical AB’s Interim report January-March 2026
2026-04-23 07:00
Regulatory MAR
Positive Group EBITDA despite market headwinds First quarter 2026 CEO comments Positive Group EBITDA despite market headwinds In the first quarter of 2026...
See More

Financial Calendar

See More